Get the Stockscreener App
1.815
8.75%
-0.185
Palisade Bio Inc stock is traded at $1.815, with a volume of 5.85M.
It is down -8.75% in the last 24 hours and up +205.20% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$2.00
Open:
$2.03
24h Volume:
5.85M
Relative Volume:
0.82
Market Cap:
$16.55M
Revenue:
-
Net Income/Loss:
$-14.07M
P/E Ratio:
-0.1297
EPS:
-13.99
Net Cash Flow:
$-12.56M
1W Performance:
-4.19%
1M Performance:
+205.20%
6M Performance:
+161.85%
1Y Performance:
-46.40%
1-Day Range:
$1.70
$2.03
1-Week Range:
$1.64
$2.28
52-Week Range:
$0.53
$4.318
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.815 | 245.12M | 0 | -14.07M | -12.56M | -13.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.62 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.57 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.99 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
803.71 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.86 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Palisade Bio Inc Stock (PALI) Latest News
Should I hold or sell Palisade Bio Inc. stock in 2025Wall Street Watch & Verified Momentum Watchlists - newser.com
Is Palisade Bio Inc. showing signs of accumulation2025 Volume Leaders & Growth Focused Entry Reports - newser.com
Palisade Bio Receives Canadian Patent for Composition of Product Candidate PALI-2108 - MarketScreener
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 - The Manila Times
Palisade Bio receives Canadian patent for inflammatory bowel drug - Investing.com
Palisade Bio Announces Grant of Patent for PALI-2108, a First-in-Class PDE4 Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis - Quiver Quantitative
PALI-2108 patent No. 3,174,137 protects drug through May 28, 2041 — Palisade Bio targets FSCD & UC - Stock Titan
Sector ETF performance correlation with Palisade Bio Inc.July 2025 Action & Risk Managed Trade Strategies - newser.com
Using data filters to optimize entry into Palisade Bio Inc.2025 Historical Comparison & Stock Portfolio Risk Management - newser.com
What MACD and RSI say about Palisade Bio Inc.Treasury Yields & Daily Oversold Stock Bounce Ideas - newser.com
How moving averages guide Palisade Bio Inc. tradingDip Buying & Advanced Swing Trade Entry Alerts - newser.com
Will Palisade Bio Inc. stock recover after recent dropJuly 2025 EndofMonth & Free Low Drawdown Momentum Trade Ideas - newser.com
What analysts say about Palisade Bio Inc stockResistance Breakout Alerts & Rapid Portfolio Strategies - earlytimes.in
Palisade Bio Inc. stock trend outlook and recovery pathWeekly Market Report & Weekly High Conviction Trade Ideas - newser.com
Is Palisade Bio Inc. stock dividend yield sustainableMarket Rally & Free Community Supported Trade Ideas - newser.com
Palisade Bio, Inc. Cancels Special Meeting of Stockholders - TradingView
Palisade Bio Announces Cancellation of Special Meeting of Stockholders - GlobeNewswire
Special Meeting Cancelled: Palisade Bio Withdraws Proxy Proposals After Failing to Secure Quorum - Stock Titan
Cohen's Point72 Pours $14M in This Biotech Stock That… - inkl
Statistical indicators supporting Palisade Bio Inc.’s strengthMarket Trend Summary & Stepwise Swing Trade Plans - newser.com
How to forecast Palisade Bio Inc. trends using time seriesRate Cut & Reliable Intraday Trade Alerts - newser.com
Why Palisade Bio Inc. (7NS0) stock could outperform next yearJuly 2025 Reactions & Fast Exit/Entry Strategy Plans - newser.com
Ranking Palisade Bio Inc. among high performing stocks via toolsInsider Buying & Breakout Confirmation Trade Signals - newser.com
After-Hours Surge: Turn Therapeutics Rockets 134% Post-Close On Nasdaq Debut; Biotech Stocks Rally - RTTNews
Steven Cohen Doubles The S&P 500 — And His Next Bet's All Gut - Benzinga
Biotech Stocks Surge After Hours: PCSA, PALI, And QTTB Lead On Volume And Speculation - Nasdaq
Is It Too Late to Buy Palisade Bio? - StocksToTrade
Palisade Bio Launches Phantom Unit Plan for Employees - MSN
Palisade Bio Stock Climbs To 9-Month High After $120M Stock Offering; Retail Sees More Gains Ahead - MSN
Morning Market Movers: FEMY, PALI, COSM, Seeing Big Swings - RTTNews
Morning Market Movers: SOPA, CRML, SANM, PALI See Big Swings - RTTNews
Is Palisade Bio Inc. stock bottoming outMarket Trend Report & Intraday High Probability Setup Alerts - newser.com
Understanding Palisade Bio Inc.’s price movementJuly 2025 Short Interest & Smart Money Movement Alerts - newser.com
Can Palisade Bio Inc. (7NS0) stock sustain breakout momentumJuly 2025 Drop Watch & Fast Moving Trade Plans - newser.com
Can technical indicators confirm Palisade Bio Inc.’s reversalJuly 2025 Price Swings & Daily Chart Pattern Signal Reports - newser.com
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Palisade Bio: Can It Balance the Volatility? - StocksToTrade
Published on: 2025-10-03 04:14:10 - newser.com
Using economic indicators to assess Palisade Bio Inc. potentialWeekly Profit Analysis & Weekly High Return Forecasts - newser.com
Published on: 2025-10-03 02:59:00 - newser.com
Palisade Bio (PALI) Stock Soars 30% on Securing $138M Public Offering Backed by Top Healthcare Players - parameter.io
Palisade Bio closes $138 million public offering for IBD drug development - Investing.com Nigeria
What technical patterns form on Palisade Bio Inc. (7NS0) stock charts2025 Big Picture & Daily Stock Trend Watchlist - newser.com
Palisade Bio closes $138 million public offering for IBD drug development By Investing.com - Investing.com South Africa
Palisade Bio Closes $138 Million Public Offering to Advance PALI-2108 for Ulcerative Colitis Development - Quiver Quantitative
Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option - The Manila Times
Palisade Bio Announces Closing of Upsized $138 Million - GlobeNewswire
$138M Raised: Palisade Bio Closes Upsized Offering to Fund Phase 2 PALI-2108 - Stock Titan
PALI Stock Soars: Time for Celebration? - timothysykes.com
Palisade Bio prices $120 million public offering at $0.70 per share - Investing.com Nigeria
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Palisade Bio Inc Stock (PALI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wei Binxian | Director |
Nov 21 '24 |
Option Exercise |
0.00 |
388 |
0 |
855 |
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):